Talaris Therapeutics, Inc. (TALS) News
Filter TALS News Items
TALS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TALS News Highlights
- For TALS, its 30 day story count is now at 3.
- Over the past 13 days, the trend for TALS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and GENE are the most mentioned tickers in articles about TALS.
Latest TALS News From Around the Web
Below are the latest news stories about TALARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate TALS as an investment opportunity.
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioCombined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris’ common stock to the stockholders of Tourm |
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioSpecial dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio, Inc. (“Tourmaline”) pursuant to the Agreement and Plan of Merger, da |
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsThis acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organizationNEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain techn |
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Talaris Therapeutics and Tourmaline Bio Announce Merger AgreementMerger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors Strong balance sheet expected to support three clinical trials for TOUR006 inc |
Talaris Therapeutics Announces Leadership TransitionBOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. “On behalf of the board, I would like to tha |
Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30%Key Insights Talaris Therapeutics' significant private equity firms ownership suggests that the key decisions are... |
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring PlanBOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical |
We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx ConferenceBOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2 |